Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This study is a single arm, pilot study of pazopanib in patient with FGFR2 amplification
Refractory solid tumor and/or specific sensitivity to pazopanib by Avatar scan that has
progressed following standard therapy or that has not responded to standard therapy or for
which there is no standard therapy.
To investigate the efficacy and safety of pazopanib in patient with Refractory solid tumor.